NI Medical Joins Innovators’ Network at American Heart Association Center for Health Technology & Innovation

NI Medical Joins Innovators’ Network at American Heart Association Center for Health Technology & Innovation

November 3, 2022 Editor 0

NI Medical Joins Innovators’ Network at American Heart Association Center for Health Technology & InnovationNI Medical Joins Innovators’ Network at American Heart Association Center for Health Technology & InnovationAmerican Heart Association consortium advances development of evidence-based health tech solutions.

TEL AVIV, Israel – November 3, 2022 – (Newswire.com)

NI Medical, the inventors of NICaS, the non-invasive hemodynamic monitoring tool, has joined the American Heart Association Center for Health Technology & Innovation’s (the Center) Innovators’ Network. The Center is focused on building and fostering health technology relationships to develop innovative and scalable solutions.

The Innovators’ Network is a healthcare-focused technology consortium that connects entrepreneurs, providers, researchers and payers. Innovators’ Network members also have access to the Association’s digital guidelines, recommendations, and best-in-class science as they develop digital healthcare technologies. Members collaborate with the Center in different ways, including the building of models for clinical outcome studies, lowering the significant cost of developing those studies independently, helping connect the science to technology, and providing evidence that a digital platform improves healthcare outcomes – a key concern for providers and payers.

“The Center aims to advance the rapid, efficient, and effective development of healthcare technology,” said Robert A. Harrington, M.D., FAHA, past president of the American Heart Association (2019-2020), volunteer chair of the American Heart Association’s Health Tech Advisory Group for the Center and Arthur L. Bloomfield professor and chair department of medicine, Stanford University. “Joining the Innovators’ Network gives members the opportunity to leverage the consortium and work toward broadening and deepening their engagement in this arena.”

“Excited to become a part of this exceptional network and join forces to deliver our unique solution for heart failure and hypertension patients management,” says Eyal Karev, CEO of NI Medical.

About NI Medical

NI Medical joins the Innovators’ Network, bringing with them NICaS, a non-invasive, cost-effective and highly validated hemodynamic management solution. 

NICaS is the only whole-body bioimpedance tool that has extensive clinical validation and accuracy capabilities equal to the gold standard (Thermodilution) with extremely high reproducibility. The solution’s greatness lies in its ability to provide the cause for the patient’s hemodynamic instability – and not only the symptom.

NI Medical presents significant expertise in bioimpedance technology globally. Having developed NICaS, the only whole-body noninvasive hemodynamic management solution, the company has been active globally and in the U.S. market for several years. The solution allows for improved personalized patient therapy, mainly in heart failure and hypertension disease management, as well as other chronic conditions. The solution is highly validated from technology, clinical and commercial perspectives. 

MEDIA CONTACT:

Jenny Chernikh
[email protected]

Contact Information:

Jenny Chernikh

Marketing Manager

[email protected]

+9720503032998

Press Release Service
by
Newswire.com

Original Source:

NI Medical Joins Innovators’ Network at American Heart Association Center for Health Technology & Innovation

Imagene Named ‘Oncology Innovation of the Year’ at 2022 BioTech Breakthrough Awards

Imagene Named ‘Oncology Innovation of the Year’ at 2022 BioTech Breakthrough Awards

November 3, 2022 Editor 0

Imagene Named ‘Oncology Innovation of the Year’ at 2022 BioTech Breakthrough AwardsImagene Named ‘Oncology Innovation of the Year’ at 2022 BioTech Breakthrough AwardsAnnual Awards Program Recognizes Innovation in the Global Life Sciences and Biotechnology Industry

TEL AVIV, Israel – November 3, 2022 – (Newswire.com)

Imagene, an emerging leader in the field of AI-based precision oncology, today announced it has been selected as “Oncology Innovation of the Year” in the second annual BioTech Breakthrough Awards program conducted by BioTech Breakthrough, a leading independent market intelligence organization that evaluates and recognizes standout life sciences and biotechnology companies, products and services around the globe.

The mission of the annual BioTech Breakthrough Awards program is to conduct the industry’s most comprehensive analysis and evaluation of the top companies, solutions and products in the life sciences and biotechnology industry today. This year’s program attracted more than 1,350 nominations from over 12 different countries throughout the world. Imagene’s AI-based Biomarker Detection was chosen as a breakthrough innovation in the field of Medical Technology.

Imagene is a pioneer startup in the Digital Genomics space. Using computer vision algorithms, the company can detect in real-time cancerous genomic alterations directly from the biopsy slide (H&E) scanned image. The idea behind Imagene’s innovative development aligns with the notion that actionable (driver) genomic alterations will have a morphological effect on the tissue in a resolution that is impossible for the human eye to detect, but AI and deep learning models can. 

“We are honored to be recognized among these great Life Science and BioTech innovators as we continue to advance precision oncology in the fight against cancer,” said Dean Bitan, co-founder and CEO at Imagene. “The cancer diagnosis process has evolved to include crucial genomic information; however, long turnaround time, tissue, and cost make its availability limited. Identifying gene alterations is key for improving patient care and guiding targeted therapeutic decisions; physicians should be able to make optimal treatment decisions in a timely and accurate manner. The availability of rapid molecular analysis can sometimes be the difference between life and death.”

“Based on the NCCN guidelines, the identification of patient-specific actionable genomic alterations serves as the basis foundation of precision oncology and is utilized routinely for optimal and personalized treatment decisions that drive higher response and mortality rates. The need to use biological specimens and the extended time needed for the analysis and interpretation, as well as inadequate tissue biopsies result in patients not getting life-saving treatment quickly enough,” said Bryan Vaughn, Managing Director of BioTech Breakthrough Awards. “Imagene’s innovative solution opens the path to fast and accurate cancer diagnosis, demonstrating the huge advancement that AI-based genomic testing can offer to cancer patients’ care. All our deep congratulations on winning ‘Oncology Innovation of the Year!'” 

Imagene has developed 28 different models for actionable alterations across eight cancer types, including Lung, Colorectal, Bladder, Breast, Ovary, Hematology, Thyroid, and brain cancer. The detection accuracy level aligns with the current gold-standard methodologies showing an average sensitivity that is superior to the standard of care. Imagene real-time image-based biomarker detection takes about two minutes, it reduces cost and time significantly with high scalability and seamless integration with routine workflows.

About Imagene

Imagene is a precision oncology diagnosis company with the mission to assist cancer patients in receiving the optimal treatment medicine can offer by leveraging AI to detect, in real-time, a broad range of cancerous biomarkers and clinical insights using only digitized biopsy images. Its multidisciplinary team is composed of a diverse group of experts from the fields of science, medicine, and deep learning. Imagene collaborates with top-tier medical centers and pharmaceutical companies worldwide, striving for fast and accurate cancer diagnosis, profiling patients for clinical trials, and accelerating the drug development process. For more information, visit Imagene-AI.com.

About BioTech Breakthrough

Part of Tech Breakthrough, a leading market intelligence and recognition platform for global technology innovation and leadership, the BioTech Breakthrough Awards program is devoted to honoring excellence in life science and biotechnology solutions, services, and companies. The BioTech Breakthrough Awards provide public recognition for the achievements of biotechnology companies and products in categories including BioPharma, Genomics, Therapeutics, Food Science and BioAgriculture, and more. For more information, visit BioTechBreakthroughawards.com

Contact Information:

Avital Rabani

Head of Marketing

[email protected]

Press Release Service
by
Newswire.com

Original Source:

Imagene Named ‘Oncology Innovation of the Year’ at 2022 BioTech Breakthrough Awards

India to overtake China as world’s most populous country – BBC News

India to overtake China as world’s most populous country – BBC News

November 2, 2022 Siver 0

India to overtake China as world’s most populous country – BBC NewsIndia is set to surpass China as having the world’s largest population next year, according to figures released by the United Nations. The two countries currently both have more than 1.4 billion people, but China’s birth rate is slower. The UN says by 2050, India will have 1.6 billion people, while China will have 1.3 […]

Ariana Grande Reveals Why Pete Davidson Was Toxic

Ariana Grande Reveals Why Pete Davidson Was Toxic

November 2, 2022 ShowBiz editor 0

Ariana Grande Reveals Why Pete Davidson Was ToxicAriana Grande Reveals Why Pete Davidson Was Toxic From petty shade-throwing to writing songs – this relationship has seen it all we all have Ariana Grande and Pete Davidson to thank for literally redefining the idea of a rebound relationship! So, was their whirlwind romance really that toxic? And you won’t believe what Ariana said […]